Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Mid Cap Fund median (34 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 03 Apr 2006 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty Midcap 150 history starts 14 Jan 2019, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | UTI - Mid Cap Fund |
|---|---|
| 03 Apr 2006 | ₹100.00 |
| 14 Dec 2007 | ₹130.76 |
| 26 Aug 2009 | ₹91.34 |
| 08 May 2011 | ₹124.81 |
| 17 Jan 2013 | ₹145.20 |
| 30 Sep 2014 | ₹276.45 |
| 11 Jun 2016 | ₹327.84 |
| 21 Feb 2018 | ₹447.42 |
| 04 Nov 2019 | ₹400.95 |
| 16 Jul 2021 | ₹695.50 |
| 28 Mar 2023 | ₹703.14 |
| 08 Dec 2024 | ₹1264.69 |
| 20 Aug 2026 | ₹1300.71 |
| Metric | UTI · Regular NAV ₹321.41 Very High risk ★★☆☆☆ | Category median Mid Cap Fund · 34 funds |
|---|---|---|
| +5.59% | +8.71% | |
| +13.78% | +18.06% | |
| +13.38% | +16.16% | |
| +13.65% | +15.69% | |
| +13.41% | +16.93% | |
| +13.01% | — | |
| +16.89% | +19.07% | |
| +16.75% | +16.56% | |
| +16.76% | +16.43% | |
| Risk | ||
| 15.29% | 16.23% | |
| 0.48 | 0.74 | |
| 0.65 | 1.00 | |
| -68.39% | -37.39% | |
| Nifty Midcap 150 | — | |
| -3.15% | +0.94% | |
| 0.94 | 0.94 | |
| 89.1% | 96.2% | |
| 101.4% | 90.1% | |
| 1.96% | 2.04% | |
| ₹11,737Cr | ₹7,594Cr | |
| 1.00% | — | |
| None | — | |
| ₹500 | — | |
| ₹5.00K | — | |
| 25% | 41% | |
| Vishal Chopda | — | |
| 03 Apr 2006 | — | |
| 91 | — | |
| 22.2% | — | |
| 0.9% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.